KR900702050A - 축색성장 조절인자 - Google Patents

축색성장 조절인자

Info

Publication number
KR900702050A
KR900702050A KR1019900701436A KR900701436A KR900702050A KR 900702050 A KR900702050 A KR 900702050A KR 1019900701436 A KR1019900701436 A KR 1019900701436A KR 900701436 A KR900701436 A KR 900701436A KR 900702050 A KR900702050 A KR 900702050A
Authority
KR
South Korea
Prior art keywords
proteins
metalloproteases
present
inhibitors
treatment
Prior art date
Application number
KR1019900701436A
Other languages
English (en)
Other versions
KR100196540B1 (ko
Inventor
마틴 이. 샤론
파이어렌리코 더블유 카로니
파울로 에이. 파가네티
Original Assignee
에어지훙스디어크찌온 오브 더 캔톤 쮜리히
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1989/001321 external-priority patent/WO1989010098A1/en
Priority claimed from US07/401,212 external-priority patent/US5684133A/en
Application filed by 에어지훙스디어크찌온 오브 더 캔톤 쮜리히 filed Critical 에어지훙스디어크찌온 오브 더 캔톤 쮜리히
Publication of KR900702050A publication Critical patent/KR900702050A/ko
Application granted granted Critical
Publication of KR100196540B1 publication Critical patent/KR100196540B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/06—Chelate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
KR1019900701436A 1988-11-04 1989-11-02 축색성장 조절인자 KR100196540B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26794188A 1988-11-04 1988-11-04
US267,941 1988-11-04
PCT/US1989/001321 WO1989010098A1 (en) 1988-04-21 1989-04-05 Stimulation of chemotaxis by chemotactic peptides
US401212 1989-08-30
US07/401,212 US5684133A (en) 1988-11-04 1989-08-30 Neurite growth regulatory factors, antibodies thereto, and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
KR900702050A true KR900702050A (ko) 1990-12-05
KR100196540B1 KR100196540B1 (ko) 1999-06-15

Family

ID=26952762

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900701436A KR100196540B1 (ko) 1988-11-04 1989-11-02 축색성장 조절인자

Country Status (8)

Country Link
US (2) US6025333A (ko)
EP (1) EP0396719B1 (ko)
KR (1) KR100196540B1 (ko)
AT (1) ATE124726T1 (ko)
AU (2) AU652537B2 (ko)
DE (1) DE68923362T2 (ko)
DK (1) DK160190A (ko)
WO (1) WO1990005191A1 (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396719B1 (en) * 1988-11-04 1995-07-05 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
AU2152092A (en) * 1991-06-24 1993-01-25 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
HU220795B1 (hu) 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
EP0634939A1 (en) * 1993-02-11 1995-01-25 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
US6576607B1 (en) 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
WO1996032959A1 (en) * 1995-04-19 1996-10-24 Acorda Therapeutics Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same
WO1997020928A1 (fr) 1995-12-06 1997-06-12 Sumitomo Pharmaceuticals Company, Limited Nouvelle semaphorine z et gene la codant
CA2265500C (en) 1996-09-11 2010-04-13 Sumitomo Pharmaceuticals Co., Ltd. Novel semaphorin gene: semaphorin y
EP0945505A4 (en) 1996-10-09 2002-11-27 Sumitomo Pharma NEW GENE OF SEMAPHORIN: SEMAPHORIN W
AU4964097A (en) 1996-11-15 1998-06-10 Sumitomo Pharmaceuticals Company, Limited Novel semaphorin genes (i)
CA2331154A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
CN1721444A (zh) 1998-11-06 2006-01-18 苏黎世大学 Nogo基因的核苷酸序列和蛋白序列以及基于其的方法
NZ520065A (en) 2000-01-12 2006-02-24 Univ Yale Nogo receptor-mediated blockade of axonal growth
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
DK1325130T3 (da) * 2000-10-06 2010-05-25 Univ Yale Nogo-Receptorhomologer
EP1805209A4 (en) * 2004-10-01 2008-04-02 Univ Yale NOGO-A POLYPEPTIDE FRAGMENTS, VARIANT OF NOGO RECEPTOR-1 POLYPEPTIDES AND USE
CA2594919A1 (en) * 2005-01-24 2006-08-03 Alnylam Pharmaceuticals, Inc. Rnai modulation of the nogo-l or nogo-r gene and uses thereof
US7893032B2 (en) * 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
WO2007014075A2 (en) 2005-07-21 2007-02-01 Alnylam Pharmaceuticals, Inc. Rnai modulation of the rho-a gene in research models
JP2009505665A (ja) * 2005-08-25 2009-02-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｎｏｇｏ受容体ポリペプチドおよびポリペプチドフラグメント、ならびにそれらの使用
KR100756423B1 (ko) 2005-10-27 2007-09-07 한국과학기술연구원 성선자극호르몬 수용체를 바이오마커로 이용한 마이엘린의탐색방법
KR20080073748A (ko) * 2005-11-16 2008-08-11 노파르티스 아게 척수 손상에서의 항-ｎｏｇｏ-ａ 항체 치료를 위한바이오마커
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用
WO2008064292A2 (en) 2006-11-21 2008-05-29 Abbott Laboratories Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287184A (en) * 1977-11-23 1981-09-01 The Massachusetts General Hospital Process for healing wounds
US4407744A (en) * 1977-11-23 1983-10-04 Young David M Process for obtaining nerve growth factor
US4230691A (en) * 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
CA1173823A (en) * 1980-08-26 1984-09-04 Leonard M. Hjelmeland Nondenaturing zwitterionic detergent for membrane biochemistry
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
EP0155433A1 (en) * 1984-03-23 1985-09-25 Adriano Fontana Immunosuppressant factor
CA1341401C (en) * 1984-03-23 2002-11-26 Adriano Fontana Immunosuppressant factor derived from human glioblastoma cells
US4803163A (en) * 1984-06-04 1989-02-07 E. I. Du Pont De Nemours And Company Preparation of a protein fraction exhibiting cell growth-inhibiting activity
EP0233838A3 (en) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
EP0396719B1 (en) * 1988-11-04 1995-07-05 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors

Also Published As

Publication number Publication date
DK160190D0 (da) 1990-07-03
AU7435494A (en) 1994-12-15
EP0396719A1 (en) 1990-11-14
AU680932B2 (en) 1997-08-14
DK160190A (da) 1990-09-03
US6025333A (en) 2000-02-15
DE68923362D1 (de) 1995-08-10
WO1990005191A1 (en) 1990-05-17
AU652537B2 (en) 1994-09-01
ATE124726T1 (de) 1995-07-15
EP0396719B1 (en) 1995-07-05
US6103232A (en) 2000-08-15
KR100196540B1 (ko) 1999-06-15
DE68923362T2 (de) 1996-03-28
AU4528089A (en) 1990-05-28

Similar Documents

Publication Publication Date Title
KR900702050A (ko) 축색성장 조절인자
HU9601244D0 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
ATE212237T1 (de) Verwendung von neuronalen fötalen zellinien für transplantationstherapie
DE60027431D1 (de) Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
ATE288490T1 (de) Neue menschliche cdc25 gene, kodierte produkte und ihre verwendung
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
ATE281840T1 (de) Behandlung von diarrhoe
ATE301459T1 (de) Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
NO961478L (no) Levobupivacaine anvendelig for kontroll av kronisk smerte
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69923998D1 (de) Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
KR970703784A (ko) 브로멜라인의 의약적 용도
WO1993000427A3 (en) Neurite growth regulatory factors
DE69616792D1 (de) Verwendung von lemellarin alkaloiden in therapeutischen verfahren
ATE355057T1 (de) Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen
DE69534753D1 (de) Nierenpolycystose-gen
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
WO2024040030A3 (en) Treating protein misfolding disorders
ES8105392A1 (es) Procedimiento de obtencion de una solucion de aminoacidos y peptidos de origen animal por proceso enzimatico
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
NO944127L (no) Blandinger og fremgangsmåter for regulering av IL-6 produksjon in vivo

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100210

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee